Zhongguo gu shang = China journal of orthopaedics and traumatology · 2025
[A cohort study on treatment of intermission period of gout with Quzhuo Tongbi formula ()combined with febuxostat].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Mei-Fei, Zhang Jing-Ya, Shi Wei-Man, Zhang Yi, Xie Zhi-Jun, Huang Ji-Yong, Wen Cheng-Ping, Zhou Dong-Hai, Wang Qiao
Аннотация
OBJECTIVE: To explore efficacy and safety of Quzhuo Tongbi formula ()combined with febustat in treating interlude period of gout (spleen deficiency and dampness obstruction type).
METHODS: From July 2024 to April 2025, 102 patients with gout during intermission period were selected for a cohort study and divided into Western medicine group and Chinese and Western group. There were 51 male patients in Western medicine group, aged with an age of (43.59±12.18) years old and the average courses of disease was (91.04±82.26) months. There were 51 patients in Chinese and Western group, including 49 males and 2 females with an average age of (47.67±11.75) years old, and the average course of disease was (92.41±85.92) months. The Western medicine group was took febuxotropic orally, while Chinese and Western medicine group was took Quzhuo Tongbi formula() combined with febuxotropic orally, 12 weeks constituted as 1 course of treatment, and both groups were treated for 1 course in totally. The changes of serum uric acid (SUA), total cholesterol (TC), and triglycerides (TG), low-density lipoprotein (LDL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (Scr), and blood urea nitrogen (BUN) between two groups before and after treatment were detected and compared; numeric rating scale (NRS), patient global assessment (PGA), and TCM syndrome scores before and after treatment were compared;the number of gout attacks within 12 weeks and adverse reactions during treatment process were recorded.
RESULTS: Totally 99 patients were finally observed clinically, including 50 patients in Western group and 49 patients in Chinese and Western groups. After 12 weeks of treatment, the indicators such as SUA, Scr and BUN in Western medicine group were decreased compared with those of before treatment(P<0.01), and the indicators such as SUA, TC, TG, LDL, ALT, AST, Scr and BUN in Chinese and Western medicine group were decreased significantly compared with those of before treatment (P<0.05). Moreover, the improvement of indicators such as SUA, LDL, ALT, AST, and Scr in Chinese and Western medicine group were better than those of in Western medicine group(P<0.05). During the treatment period, the frequency of gout attacks in Chinese and Western medicine group was lower than that in Western medicine group(P<0.01). The NRS, PGA scores and TCM syndrome scores of both groups were decreased compared with those of before treatment (P<0.01), and the improvement of NRS and PGA scores in Chinese and Western medicine group were better than those of in Western medicine group (P<0.01). One patient developed liver function damage due to taking medicine in Western medicine group, while there were no adverse reactions in Chinese and Western medicine group.
CONCLUSION: Quzhuo Tongbi formula() combined with febuxostat has definite clinical efficacy and good safety in the treatment of gout during intermission period, and it plays a positive role in preventing recurrence.
METHODS: From July 2024 to April 2025, 102 patients with gout during intermission period were selected for a cohort study and divided into Western medicine group and Chinese and Western group. There were 51 male patients in Western medicine group, aged with an age of (43.59±12.18) years old and the average courses of disease was (91.04±82.26) months. There were 51 patients in Chinese and Western group, including 49 males and 2 females with an average age of (47.67±11.75) years old, and the average course of disease was (92.41±85.92) months. The Western medicine group was took febuxotropic orally, while Chinese and Western medicine group was took Quzhuo Tongbi formula() combined with febuxotropic orally, 12 weeks constituted as 1 course of treatment, and both groups were treated for 1 course in totally. The changes of serum uric acid (SUA), total cholesterol (TC), and triglycerides (TG), low-density lipoprotein (LDL), alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine (Scr), and blood urea nitrogen (BUN) between two groups before and after treatment were detected and compared; numeric rating scale (NRS), patient global assessment (PGA), and TCM syndrome scores before and after treatment were compared;the number of gout attacks within 12 weeks and adverse reactions during treatment process were recorded.
RESULTS: Totally 99 patients were finally observed clinically, including 50 patients in Western group and 49 patients in Chinese and Western groups. After 12 weeks of treatment, the indicators such as SUA, Scr and BUN in Western medicine group were decreased compared with those of before treatment(P<0.01), and the indicators such as SUA, TC, TG, LDL, ALT, AST, Scr and BUN in Chinese and Western medicine group were decreased significantly compared with those of before treatment (P<0.05). Moreover, the improvement of indicators such as SUA, LDL, ALT, AST, and Scr in Chinese and Western medicine group were better than those of in Western medicine group(P<0.05). During the treatment period, the frequency of gout attacks in Chinese and Western medicine group was lower than that in Western medicine group(P<0.01). The NRS, PGA scores and TCM syndrome scores of both groups were decreased compared with those of before treatment (P<0.01), and the improvement of NRS and PGA scores in Chinese and Western medicine group were better than those of in Western medicine group (P<0.01). One patient developed liver function damage due to taking medicine in Western medicine group, while there were no adverse reactions in Chinese and Western medicine group.
CONCLUSION: Quzhuo Tongbi formula() combined with febuxostat has definite clinical efficacy and good safety in the treatment of gout during intermission period, and it plays a positive role in preventing recurrence.